They are standard treatment drugs recommended by the Breast Cancer Guidelines of Chinese Society of Clinical Oncology (CSCO) [29,30], and they are also suitable for second-line treatments of advanced HER2-positive BC after tolerance of trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.